Tweets
Good news for scleroderma lung disease. Abstract OP0017 shows less decline in SSc ILD with nintedanib v placebo. Half on MMF in both groups. Less decline if on MMF but still 40% reduction in active v placebo in both subsets and combination seemed safe. @RheumNow #EULAR2019 https://t.co/1CJ4sggZsj
Janet Pope @Janetbirdope ( View Tweet )
7 years 2 months ago
Go Ai Li! Winner of clinical science abstract awards @Monash_FMNHS @RheumNow #eular2019 https://t.co/7cLYREEAlY
Alberta Hoi @tuna0sashimi ( View Tweet )
7 years 2 months ago
Looking forward to joining Jack and the rest of the team in reporting for @RheumNow from #EULAR2019 in sunny Madrid this week! https://t.co/WLhaq2KtsR https://t.co/BJGxfDKfcA
David Liew @drdavidliew ( View Tweet )
7 years 2 months ago
Plenary session of JIA post TNFI failure OP0016 from 2 UK registries by Kearsley-Fleet shows no difference in 151 kids who go to 2nd TNFi vs switch to different biologic for response and retention. Either is ok. @RheumNow #EULAR2019
Janet Pope @Janetbirdope ( View Tweet )
7 years 2 months ago
UK study shows SLE admissions increased from 8.97 to 9.04 per 100,000 ( p < 0.001) between 1998 & 2015. By comparison, RA admissions rose from 71.0 to 171.6 per 100,000 ( p < 0.001). YET total bed days for SLE & RA fell by 60% and 90%, respectively https://t.co/5IeZh8o8M5
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 2 months ago
EULAR is a truly pan-European organisation fostering a multitude of activities in areas of research, patient care, and education. Learn more at #EULAR2019! #rheumatology #rheumarthritis #lupus https://t.co/sGSuKnXpNg
EULAR | The European League Against Rheumatism @eular_org ( View Tweet )
7 years 2 months ago
NHANES study shows Psoriatic arthritis found that #PsA patients report more hearing difficulties (OR 1.50, p 0.043), visit mental health provider (OR 1.62, p = 0.084), 1.62 more days of poor mental health (p = 0.033), and depression (OR 2.01, p = 0.015) https://t.co/xdh4MfWxbA
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 2 months ago
https://t.co/V10S4oVFsv would love to feature your tweets in our coverage of #EULAR2019 from Madrid. Be sure to include these 3 in your tweet- @RheumNow #EULAR2019 & the abstract # https://t.co/WqqX4w4dmd
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 2 months ago
GSK announced that the FDA has approved the IL-5 inhibitor Nucala (mepolizumab), as an autoinjector and a pre-filled safety syringe, (for use in severe eosinophilic asthma & disease eosinophilic granulomatosis with polyangiitis (EGPA) https://t.co/XXGJxLDta7
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 2 months ago
Hear nine experts talk about biosimilars in “Therapeutic Update: Biosimilars in Rheumatology”, a video series brought to viewers by Sandoz. Now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 2 months ago
US Dermatologists serving on FDA advisory panels during derm drug approval: study shows half received at least 1payment from pharma; 27% > $1000, 15% >$50K, 9% > $100K. Payments from competitors outnumbered manufacturers https://t.co/bNmjkQFOJM
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 2 months ago
The cost of healthcare in inflammatory bowel disease is >3 times a healthy population. Overall, average annual costs for patients with IBD were $22,987 compared with $6,956 without IBD, the study found. Out-of-pocket costs were more than doubled . https://t.co/FopLzw4ypU
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 2 months ago
https://t.co/V10S4oVFsv would love to feature your tweets in our coverage of #EULAR2019 from Madrid. Be sure to include these 3 in your tweet- @RheumNow #EULAR2019 & the abstract # https://t.co/WqqX4w4dmd
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 2 months ago
RheumNow Podcast is up! Info on Drug Ad Transparency, FDA CBD oil hearing, OI, TB testing, Stem Cell Clinics and more. Watch it here >>https://t.co/MbE91908Er or listen to the podcast on iTunes or SoundCloud >> https://t.co/FbEn1vWriU
Dr. John Cush @RheumNow ( View Tweet )
7 years 2 months ago
Clinical Trials Benchmark for Biosimilar Development is one of several educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 2 months ago
